These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10760259)

  • 1. Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.
    Karlstrom A; Zhong G; Rader C; Larsen NA; Heine A; Fuller R; List B; Tanaka F; Wilson IA; Barbas CF; Lerner RA
    Proc Natl Acad Sci U S A; 2000 Apr; 97(8):3878-83. PubMed ID: 10760259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.
    Barbas CF; Heine A; Zhong G; Hoffmann T; Gramatikova S; Björnestedt R; List B; Anderson J; Stura EA; Wilson IA; Lerner RA
    Science; 1997 Dec; 278(5346):2085-92. PubMed ID: 9405338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring substrate binding and discrimination in fructose1, 6-bisphosphate and tagatose 1,6-bisphosphate aldolases.
    Zgiby SM; Thomson GJ; Qamar S; Berry A
    Eur J Biochem; 2000 Mar; 267(6):1858-68. PubMed ID: 10712619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological origins of binding and catalysis in a Diels-Alderase antibody.
    Romesberg FE; Spiller B; Schultz PG; Stevens RC
    Science; 1998 Mar; 279(5358):1929-33. PubMed ID: 9506942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro abzyme evolution to optimize antibody recognition for catalysis.
    Takahashi N; Kakinuma H; Liu L; Nishi Y; Fujii I
    Nat Biotechnol; 2001 Jun; 19(6):563-7. PubMed ID: 11385462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The origin of enantioselectivity in aldolase antibodies: crystal structure, site-directed mutagenesis, and computational analysis.
    Zhu X; Tanaka F; Hu Y; Heine A; Fuller R; Zhong G; Olson AJ; Lerner RA; Barbas CF; Wilson IA
    J Mol Biol; 2004 Nov; 343(5):1269-80. PubMed ID: 15491612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes.
    Wagner J; Lerner RA; Barbas CF
    Science; 1995 Dec; 270(5243):1797-800. PubMed ID: 8525368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of functionally important residues in the pyridoxal-5'-phosphate-dependent catalytic antibody 15A9.
    Mouratou B; Stetefeld J
    Biochemistry; 2004 Jun; 43(21):6612-9. PubMed ID: 15157094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peculiarities of the Mechanism of Interactions of Catalytic Antibodies with Organophosphorus Substrates].
    Mokrushina YA; Pipiya SO; Stepanova AV; Shamborant OG; Knorre VD; Smirnov IV; Gabibov AG; Vorobiev II
    Mol Biol (Mosk); 2017; 51(6):958-968. PubMed ID: 29271960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate antibody catalysis.
    Gololobov G; Sun M; Paul S
    Mol Immunol; 1999 Dec; 36(18):1215-22. PubMed ID: 10684961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunological evolution of catalysis.
    Patten PA; Gray NS; Yang PL; Marks CB; Wedemayer GJ; Boniface JJ; Stevens RC; Schultz PG
    Science; 1996 Feb; 271(5252):1086-91. PubMed ID: 8599084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
    Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
    J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of catalytic antibody repertoire in autoimmune mice.
    Nishi Y
    J Immunol Methods; 2002 Nov; 269(1-2):213-33. PubMed ID: 12379363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies.
    Kim SH; Schindler DG; Lindner AB; Tawfik DS; Eshhar Z
    Mol Immunol; 1997; 34(12-13):891-906. PubMed ID: 9464525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
    Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
    J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interplay between binding energy and catalysis in the evolution of a catalytic antibody.
    Ulrich HD; Mundorff E; Santarsiero BD; Driggers EM; Stevens RC; Schultz PG
    Nature; 1997 Sep; 389(6648):271-5. PubMed ID: 9305839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization.
    Miyashita H; Hara T; Tanimura R; Fukuyama S; Cagnon C; Kohara A; Fujii I
    J Mol Biol; 1997 Apr; 267(5):1247-57. PubMed ID: 9150409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalytic antibodies: evolution of protein function in real time.
    Lerner RA; Janda KD
    EXS; 1995; 73():121-38. PubMed ID: 7579971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.